Horizon Quantum Computing to Establish First-of-a-Kind…

RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2021 -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and Gilbert Kinsey, PhD, PharmD, to Principal. Their promotions further strengthen the Pappas Capital team in support of the firm's continued growth and expansion.

CARY, N.C., Oct. 20, 2021 -- Two North Carolina companies, analytics leader SAS and venture investment firm Pappas Capital, are joining forces to help advance the state as a global leader in agricultural technology. The state's AgTech sector is ripe for continued growth and innovation, and technologies such as artificial intelligence, machine learning and analytics are driving innovation in digital agriculture. The collaboration between SAS and Pappas will allow select NC agriculture and food startups to gain guidance and executive leadership from Pappas and access to industry-leading analytics software, data science expertise and cloud services from SAS.

RESEARCH TRIANGLE PARK, NC, Feb. 3, 2020 -- Pappas Capital, a leading investor in early-stage life sciences companies, has appointed Karen LeVert as Venture Partner to help lead the expansion of the firm's Specialized Fund Management business, with a focus on identifying attractive investment opportunities in agricultural and other related technologies. Ms. LeVert has a proven track record of progressing early stage technologies from university research labs to commercialization, and most recently co-founded two independent innovation labs, Southeast TechInventures, Inc. (STI) and Ag TechInventures, LLC (AgTI).

RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 -- Pappas Capital, a leading investor in early-stage life sciences companies, announced today that Alex Arfaei has joined the firm as a Partner of Pappas Ventures. In his role, Mr. Arfaei will be responsible for helping to identify and evaluate investment opportunities for the firm's venture capital business. Previously, Mr. Arfaei served as a Managing Director with BMO Capital Markets, where he was a senior equity research analyst covering major pharmaceutical and biotechnology companies.